Development of a vaccine to prevent Japanese encephalitis: A brief review

International Journal of General Medicine

Volumn 2, Issue , 2009, Pages 195-200

  Wiwanitkit, Viroj ^a  

^a WIWANITKIT HOUSE   (Thailand)

Author keywords

Concept; Development; Japanese encephalitis; Prevention; Vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; PHENOBARBITAL; PHENYTOIN; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASIA; BRAIN; BRAIN DISEASE; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG CONTRAINDICATION; DRUG COST; DRUG PACKAGING; DRUG STORAGE; ELECTROENCEPHALOGRAM; EPIDEMIC ENCEPHALITIS; HUMAN; IMAGING; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE INFLAMMATION; JAPANESE ENCEPHALITIS VIRUS; LABORATORY TEST; POSTMARKETING SURVEILLANCE; PREVENTIVE MEDICINE; REVIEW; SEIZURE; VACCINATION; VECTOR CONTROL;

EID: 77953380896     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/ijgm.s6281     Document Type: Review

References (71)

1. Wiwanitkit V. Japanese encephalitis. J Ped infect Dis. 2007;4(2): 183-192.
2. Halstead SB, Jacobson J. Japanese encephalitis. Adv Virus Res. 2003;61:103-138.
3. Watanabe T. Japanese encephalitis. Nippon Rinsho. 2003; 61 Suppl 2:95-99.
4. Solomon T. Recent advances in Japanese encephalitis. J Neurovirol. 2003;9(2):274-283.
5. Kawakatsu S. Encephalitis and psychosis. Ryoikibetsu Shokogun Shirizu. 2003;(40):303-306.
6. Solomon T. Exotic and emerging viral encephalitides. Curr Opin Neurol. 2003;16(3):411-418.
7. Kurane I. Japanese encephalitis virus. Nippon Rinsho. 2003; 61 Suppl 3:491-493.
8. Tolle MA. Mosquito-borne diseases. Curr Probl Pediatr Adolesc Health Care. 2009;39(4):97-140.
9. van den Hurk AF, Ritchie SA, Mackenzie JS. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol. 2009; 54:17-35.
10. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet. 2008; 371(9611):500-509.
11. Weaver SC. Host range, amplification and arboviral disease emergence. Arch Virol Suppl. 2005;(19):33-44.
12. Konishi E. Clinical and epidemiological aspects of Japanese encephalitis. Nippon Rinsho. 2005;63(12):2138-2142.
13. Wada Y. Control of Japanese encephalitis vectors. Southeast Asian J Trop Med Public Health. 1989;20(4):623-626.
14. Philip Samuel P, Tyagi BK. Diagnostic methods for detection and isolation of dengue viruses from vector mosquitoes. Indian J Med Res. 2006;123(5):615-628.
15. Lounibos LP. Invasions by insect vectors of human disease. Annu Rev Entomol. 2002;47:233-266.
16. Saxena V, Dhole TN. Preventive strategies for frequent outbreaks of Japanese encephalitis in Northern India. J Biosci. 2008;33(4):505-514.
17. Barboza P, Tarantola A, Lassel L, Mollet T, Quatresous I, Paquet C. Emerging viral infections in South East Asia and the Pacific region. Med Mal Infect. 2008;38(10):513-523.
18. Bhargava A, Chatterjee B. Chikungunya fever, falciparum malaria, dengue fever, Japanese encephalitis... are we listening to the warning signs for public health in India? Indian J Med Ethics. 2007;4(1):18-23.
19. Arai S, Matsunaga Y, Takasaki T, et al; Vaccine Preventable Diseases Surveillance Program of Japan. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. Jpn J Infect Dis. 2008;61(5):333-338.
20. Fontenille D. Transmission cycles of arboviruses in Madagascar. Arch Inst Pasteur Madagascar. 1989;55(1):7-317.
21. Mackenzie JS, Broom AK, Hall RA, et al. Arboviruses in the Australian region, 1990 to 1998. Commun Dis Intell. 1998;22(6): 93-100.
22. Dunstan RA, Seed CR, Keller AJ. Emerging viral threats to the Australian blood supply. Aust N Z J Public Health. 2008;32(4): 354-360.
23. Hore C. Important unusual infections in Australia: a critical care perspective. Crit Care Resusc. 2001;3(4):262-272.
24. McCormack JG, Allworth AM. Emerging viral infections in Australia. Med J Aust. 2002;177(1):45-49.
25. Hinson VK, Tyor WR. Update on viral encephalitis. Curr Opin Neurol. 2001;14(3):369-374.
26. Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. Lancet. 2002;359(9305):507-513.
27. van-den-Hurk AF, Ritchie SA, Johansen CA, Mackenzie JS, Smith GA. Domestic pigs and Japanese encephalitis virus infection, Australia. Emerg Infect Dis. 2008;14(11):1736-1738.
28. Van Den Hurk AF, Johansen CA, Zborowski P, et al. Mosquito hostfeeding patterns and implications for Japanese encephalitis virus transmission in northern Australia and Papua New Guinea. Med Vet Entomol. 2003;17(4):403-411.
29. van den Hurk AF, Nisbet DJ, Johansen CA, Foley PN, Ritchie SA, Mackenzie JS.
30. Japanese encephalitis on Badu Island, Australia: the first isolation of Japanese encephalitis virus from Culex gelidus in the Australasian region and the role of mosquito host-feeding patterns in virus transmission cycles. Trans R Soc Trop Med Hyg. 2001;95(6):595-600.
31. Mwandawiro C, Boots M, Tuno N, Suwonkerd W, Tsuda Y, Takagi M. Heterogeneity in the host preference of Japanese encephalitis vectors in Chiang Mai, Northern Thailand. Trans R Soc Trop Med Hyg. 2000;94(3):238-242.
32. Misra UK, Kalita J. Seizures in Japanese encephalitis. J Neurol Sci. 2001;190(1-2):57-60.
33. Lam K, Tsang OT, Yung RW, Lau KK. Japanese encephalitis in Hong Kong. Hong Kong Med J. 2005;11(3):182-188.
34. Misra UK, Kalita J, Srivastava M. Prognosis of Japanese encephalitis: a multivariate analysis. J Neurol Sci. 1998;161(2):143-147.
35. Ishii T, Matsushita M, Hamada S. Characteristic residual neuropathological features of Japanese B encephalitis. Acta Neuropathol. 1977;38(3):181-186.
36. Schiøler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev. 2007;(3):CD004263.
37. Tauber E, Dewasthaly S. Japanese encephalitis vaccines - needs, flaws and achievements. Biol Chem. 2008;389(5):547-550.
38. Wiwanitkit V. Vaccination for tropical mosquito borne encephalitis. Acta Neurol Taiwan. 2009;18(1):60-63.
39. Wills MR, Sil BK, Cao JX, Yu YX, Barrett AD. Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area. Vaccine. 1992;10(12):861-872.
40. Yamashita T, Ishikawa N, Hojo F, Shimada F, Ono K. Japanese encephalitis purified vaccine. II. Purity of the mouse brain vaccine purified by ultracentrifugation. Biken J. 1970;13(1):25-38.
41. Gupta RK, Misra CN, Gupta VK, Saxena SN. An efficient method for production of purified inactivated Japanese encephalitis vaccine from mouse brains. Vaccine. 1991;9(12):865-867.
42. Aizawa C, Hasegawa S, Chih-Yuan C, Yoshioka I. Large-scale purification of Japanese encephalitis virus from infected mouse brain for preparation of vaccine. Appl Environ Microbiol. 1980;39(1):54-57.
43. Yang SE, Pan MJ, Tseng HF, Liau MY. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine - results from 30 years experience in Taiwan. Vaccine. 2006;24(14):2669-2673.
44. Hanna JN, Smith GA, McCulloch BG, Taylor CT, Pyke AT, Brookes DL. An assessment of the interval between booster doses of Japanese encephalitis vaccine in the Torres Strait. Aust N Z J Public Health. 2005;29(1):44-47.
45. Itoh H, Kobyashif F, Toda M, Takashita I, Kitagawa S. Studies on mouse brain and chick embryo tissue in connection with the preparation of Japanese encephalitis vaccine. Kitasato Arch Exp Med. 1953;26(4): 243-258.
46. Gowal D, Tahlan AK. Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India. Indian J Med Res. 1995;102:267-271.
47. Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988;319(10): 608-614.
48. El'bert LB, Semenov BF, Karaseva PS, Pervikov IuV, Krutianskaia GL. Inactivated vaccine against Japanese encephalitis. The characteristics of a purified preparation from mouse brain. Vopr Virusol. 1983; (2):196-200.
49. Fujisaki Y, Miura Y, Sugimori T, Murakami Y, Miura K. Experimental studies on vertical infection of mice with Japanese encephalitis virus. IV. Effect of virus strain on placental and fetal infection. Natl Inst Anim Health Q (Tokyo). 1983;23(1):21-26.
50. Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am. 2003;23(4):665-697.
51. Duggan ST, Plosker GL. Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs. 2009;69(1):115-122.
52. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin Biol Ther. 2009 Jul;9(7):921-931.
53. Zanin MP, Webster DE, Martin JL, Wesselingh SL. Japanese encephalitis vaccines: moving away from the mouse brain. Expert Rev Vaccines. 2003;2(3):407-412.
54. Bharati K, Vrati S. Japanese encephalitis: development of new candidate vaccines. Expert Rev Anti Infect Ther. 2006;4(2):313-324.
55. Kaur R, Vrati S. Development of a recombinant vaccine against Japanese encephalitis. J Neurovirol. 2003;9(4):421-431.
56. Davies MN, Flower DR. Harnessing bioinformatics to discover new vaccines. Drug Discov Today. 2007;12(9-10):389-395.
57. De Groot AS. Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today. 2006;11(5-6):203-209.
58. Brusic V, Petrovsky N. Immunoinformatics - the new kid in town. Novartis Found Symp. 2003;254:3-13.
59. Maecker B, von Bergwelt-Baildon, Anderson KS, Vonderheide RH, Schultze JL. Linking genomics to immunotherapy by reverse immunology - 'immunomics' in the new millennium. Curr Mol Med. 2001;1(5):609-619.
60. Li P, Zheng QS, Wang Q, et al. Immune responses of recombinant adenoviruses expressing immunodominant epitopes against Japanese encephalitis virus. Vaccine. 2008;26(46):5802-5807.
61. Lin CW, Liu KT, Huang HD, Chen WJ. Protective immunity of E. coli-synthesized NS1 protein of Japanese encephalitis virus. Biotechnol Lett. 2008;30(2):205-214.
62. Alka, Bharati K, Malik YP, Vrati S. Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice. Med Microbiol Immunol. 2007; 196(4):227-231.
63. Zhang F, Ma W, Zhang L, Aasa-Chapman M, Zhang H. Expression of particulate-form of Japanese encephalitis virus envelope protein in a stably transfected Drosophila cell line. Virol J. 2007;4:17.
64. Ge FF, Qiu YF, Yang YW, Chen PY. An hsp70 fusion protein vaccine potentiates the immune response against Japanese encephalitis virus. Arch Virol. 2007;152(1):125-135.
65. Feng GH, Liu N, Zhou Y, Zhai YZ, Li XM, Dou XG. Immunologic analysis induced by DNA vaccine encoding E protein of Beijing-1 strain derived from Japanese encephalitis virus. Intervirology. 2007;50(2): 93-98.
66. Beasley DW, Li L, Suderman MT, et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine. 2004; 22(27-28):3722-3726.
67. Lai CJ, Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res. 2003;61:469-509.
68. Jones T. ChimeriVax-JE. Acambis. Curr Opin Investig Drugs. 2003;4:1019-1022.
69. Jones T. A chimeric live attenuated vaccine against Japanese encephalitis. Expert Rev Vaccines. 2004;3(3):243-248.
70. Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003;188(8):1213-1230.
71. Lobigs M, Larena M, Alsharifi M, Lee E, Pavy M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their crossprotective values against Murray Valley encephalitis virus. J Virol. 2009;83(6):2436-2445.